Anacetrapib add-on therapy in adults with heterozygous familial hypercholesterolemia on statins

Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Anacetrapib plus ongoing statin therapy with Placebo plus ongoing statin therapy (2 arms). Primary endpoints: Percent change from baseline in LDL cholesterol at Week 52 and Safety and tolerability through 52 weeks. Started Feb 2012; status: active, not recruiting.